Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers seeking to protect patents covering their products. A key factor in each challenge was how to demonstrate commercial success of the product and the nexus between that success and the patents-in-suit with respect to the issue of non-obviousness of the patents-in-suit.
Dr. Bell was supported in these cases by CRA consultants including Andrew Tepperman, Justin Ho, Cavay Ip, Archan Ruparel, and Natalie Nah.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...